All In Biotech

Drug Trial Radar · NCT07098403

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase Ⅲ Study to Evaluate the Efficacy and Safety of SHR-1905 in Subjects With Severe Uncontrolled Asthma

Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 408 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

408

Planned (sponsor's estimate)

Start

Sep 3, 2025

Primary completion

Jan 2028

Study completion Jun 2028

Sponsor

Sponsor type
Industry
First posted
Aug 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase III study of SHR-1905 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of SHR-1905 in subjects with severe uncontrolled asthma.

Conditions

  • Asthma

Interventions

  • SHR-1905 InjectionDrug

    SHR-1905 injection.

  • SHR-1905 Placebo InjectionDrug

    SHR-1905 placebo Injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual asthma exacerbation rateTime frame: During 48 weeks of treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.